Stock MTNB MATINAS BIOPHARMA HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Matinas BioPharma Holdings, Inc.

Equities

MTNB

US5768101058

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
0.166 USD +0.61% Intraday chart for Matinas BioPharma Holdings, Inc. -2.35% -23.22%
May. 09 Transcript : Matinas BioPharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09 Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.

Number of employees: 32

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Pharmaceutical Products
100.0 %
3 100.0 % 1 100.0 % -65.62%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
3 100.0 % 1 100.0 % -65.62%

Managers

Managers TitleAgeSince
Jerome Jabbour FOU
 Founder 50 13-04-30
Keith Kucinski DFI
 Director of Finance/CFO 55 19-01-02
Hui Liu CTO
 Chief Tech/Sci/R&D Officer 56 20-11-30
James Ferguson CTO
 Chief Tech/Sci/R&D Officer 70 19-02-24
Theresa Matkovits PRN
 Corporate Officer/Principal 56 18-10-14
Thomas Hoover PRN
 Corporate Officer/Principal 55 21-12-05

Members of the board

Members of the board TitleAgeSince
Herbert Conrad FOU
 Founder 91 13-04-30
Natasha Giordano BRD
 Director/Board Member 62 20-09-13
Eric Ende CHM
 Chairman 55 17-04-02
James Scibetta BRD
 Director/Board Member 59 13-10-31
Matthew Wikler BRD
 Director/Board Member 74 17-12-31
Kathryn Corzo BRD
 Director/Board Member 63 21-08-31
Jerome Jabbour FOU
 Founder 50 13-04-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 250,816,164 244,482,252 ( 97.47 %) 0 97.47 %

Shareholders

NameEquities%Valuation
Vanguard Global Advisers LLC
3.715 %
9,317,838 3.715 % 2 M $
Herbert Conrad
1.872 %
4,694,566 1.872 % 854 411 $
Sargent Investment Group LLC
1.440 %
3,610,500 1.440 % 657 111 $
BlackRock Institutional Trust Co. NA
0.9897 %
2,482,400 0.9897 % 451 797 $
Geode Capital Management LLC
0.8514 %
2,135,457 0.8514 % 388 653 $
Arkadios Wealth Advisors LLC
0.6475 %
1,624,000 0.6475 % 295 568 $
Neville, Rodie & Shaw, Inc.
0.4614 %
1,157,332 0.4614 % 210 634 $
JTC Employer Solutions Trustee Ltd.
0.3090 %
775,000 0.3090 % 141 050 $
STATE STREET CORPORATION
0.2631 %
659,871 0.2631 % 120 097 $
James Scibetta
0.2591 %
649,958 0.2591 % 118 292 $

Company contact information

Matinas BioPharma Holdings, Inc.

1545 Route 206 South Suite 302

07921-9999, Bedminster

+908 484 8805

http://www.matinasbiopharma.com
address Matinas BioPharma Holdings, Inc.(MTNB)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.166 USD
Average target price
0.8667 USD
Spread / Average Target
+422.09%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MATINAS BIOPHARMA HOLDINGS, INC. Stock Matinas BioPharma Holdings, Inc.
-23.22% 41.64M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+12.30% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.15% 106B
BIONTECH SE Stock BioNTech SE
-8.14% 23.4B
ARGENX SE Stock argenx SE
-1.69% 21.78B
GENMAB A/S Stock Genmab A/S
-10.60% 18.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.25% 16.72B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.33% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.80% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.03% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MTNB Stock
  4. Company Matinas BioPharma Holdings, Inc.